A Review Of active ingredient in ketamine
Within the secondary analysis, the considerably less conservative but clinically meaningful criterion of stable response (described for a 50% or more reduction in MADRS from baseline for 2 months) was used. Of the patients who attained steady response, twenty five.8% while in the esketamine group and fifty seven.six% in the placebo group relapsed,